The Food and Drug Administration (FDA) will hold a public hearing on May 31, 2019, “to obtain scientific data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds.”1 This offers those within the cannabis industry a unique opportunity to speak on their concerns and interests over regulation of cannabis plants and cannabis-derived products, including Cannabidiol (CBD).
Topics the FDA is considering and collecting data and information are as follows:
- Possible health and safety risks related to cannabis and cannabis-derived products;
- Manufacturing and product quality of cannabis and cannabis-derived products (not including those marked as drugs already in compliance with the Food, Drug & Cosmetic Act (FDCA); and
- The marketing, labeling and selling of cannabis and cannabis-derived products (other than those drug products previously approved by FDA for human and animal use).
To read more on the FDA’s public hearing, please visit reedsmith.com